---
schema_version: "secwatch.filing_event.v1"
accession: "0001367644-23-000024"
form_type: "8-K"
ticker: "EBS"
cik: "0001367644"
company_name: "Emergent BioSolutions Inc."
filed_at: "2023-02-27T23:59:59+00:00"
generated_at: "2026-06-18T23:21:43.926956+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Emergent BioSolutions Q4 2022 net loss $88M, revenue $331M (-54% YoY); FY2023 guidance issued

## Summary
- Q4 2022 total revenues $330.7M vs $723.2M in Q4 2021; net loss $88.0M vs net income $189.3M.
- Full year 2022 revenues $1,120.9M (-37% YoY); net loss $223.8M vs net income $230.9M.
- FY2023 guidance: revenues $1.1-1.2B, adjusted EBITDA $75-125M, adjusted gross margin 41-44%.
- Agreed to sell travel health business to Bavarian Nordic for up to $380M; FDA priority review for NARCAN OTC.
- Eliminated 132 positions with annualized savings >$60M; DoD RSDL contract valued up to $379.6M.

## SEC filing metadata
- accession: 0001367644-23-000024
- form_type: 8-K
- ticker: EBS
- cik: 0001367644
- company_name: Emergent BioSolutions Inc.
- filed_at: 2023-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1367644/000136764423000024/0001367644-23-000024-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1367644/000136764423000024/ebs-20230227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001367644-23-000024
- JSON: https://secwatch.observer/filing/0001367644-23-000024.json
- Plain text: https://secwatch.observer/filing/0001367644-23-000024.txt

## Key facts
- Earnings Releases
  Emergent BioSolutions Inc. reported Full Year 2022 results: revenue $1,120.9, net income $(223.8), EPS $(4.47). Guidance initiated.
  - Period: Full Year 2022
  - Revenue: $1,120.9
  - Net income: $(223.8)
  - EPS: $(4.47)
  - Guidance: initiated
  - Result: reported results
  source text: Full Year 2022 vs. Full Year 2021 ($ in millions, except per share amounts) Full Year 2022 Full Year 2021 % Change Total Revenues $1,120.9 $1,792.7 (37)% Net Income (Loss) $(223.8) $230.9 * Net Income (Loss) per Diluted Share $(4.47) $4.27 *
  evidence_url: https://www.sec.gov/Archives/edgar/data/1367644/000136764423000024/0001367644-23-000024-index.htm
- Earnings Releases
  Emergent BioSolutions Inc. reported Q4 2022 results: revenue $330.7, net income $(88.0), EPS $(1.76). Guidance initiated.
  - Period: Q4 2022
  - Revenue: $330.7
  - Net income: $(88.0)
  - EPS: $(1.76)
  - Guidance: initiated
  - Result: reported results
  source text: Q4 2022 vs. Q4 2021 ($ in millions, except per share amounts) Q4 2022 Q4 2021 % Change Total Revenues $330.7 $723.2 (54)% Net Income (Loss) $(88.0) $189.3 * Net Income (Loss) per Diluted Share $(1.76) $3.50 *
  evidence_url: https://www.sec.gov/Archives/edgar/data/1367644/000136764423000024/0001367644-23-000024-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.